Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2026)

Cogent Biosciences (COGT) has reported Cash & Equivalents for 10 consecutive years, with $241.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 91.43% year-over-year to $241.2 million; the TTM figure through Mar 2026 stood at $241.2 million (up 91.43% YoY), while the FY2025 annual figure was $312.0 million, up 217.84% from the prior year.
• Cash & Equivalents declined to $241.2 million in Q1 2026 per COGT's latest filing, from $312.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $325.6 million in Q2 2022 and bottomed at $53.2 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $161.4 million across 5 years, with a median of $139.9 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 61.95% — and 2025, when it surged 217.84%.
• Cogent Biosciences' Cash & Equivalents stood at $139.9 million in 2022, then sank by 61.95% to $53.2 million in 2023, then soared by 84.42% to $98.2 million in 2024, then soared by 217.84% to $312.0 million in 2025, then dropped by 22.69% to $241.2 million in 2026.
• Business Quant data shows COGT's Cash & Equivalents at $241.2 million in Q1 2026, $312.0 million in Q4 2025, and $125.3 million in Q3 2025.